ArticleJournal of thoracic disease2024
Protocol of a single-arm, multicenter, phase III trial for selective lymph node dissection in cT1N0M0 invasive non-small cell lung cancer with consolidation-tumor ratio >0.5 located in the apical segment: Eastern Cooperative Thoracic Oncology Projects ECTOP-1018 (SELLAS study).
Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06031246 (Selective Lymph Node Dissection for cT1N0M0 Invasive Non-small Cell Lung Cancer With CTR>0.5 Located in the Apical Segment), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Selective Lymph Node Dissection for cT1N0M0 Invasive Non-small Cell Lung Cancer With CTR>0.5 Located in the Apical Segment: a Single-arm, Multi-center, Phase III Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lymph node dissection (LND) is the standard procedure for operable invasive non-small cell lung cancer (NSCLC), for radical cure and lymph node (LN) staging. However, its necessity is controversial in early-stage patients without LN metastasis, as evidence shows it could not improve prognosis and may cause surgical complications. Methods: We initiated a prospective, multi-center, single-arm, phase III trial to confirm the non-inferior survival rate of surgery sparing the lower mediastinal LND in apical cT1N0M0 invasive NSCLC with consolidation-tumor ratio (CTR) >0.5 at high-resolution computed tomography (CT) scan. We plan to enroll a total of 634 patients with invasive NSCLC with predominantly non-lepidic subtype confirmed by intraoperative frozen pathology, who will receive radical lung cancer surgery but waiver lower mediastinal LND. The primary endpoint is recurrence-free survival (RFS), the secondary endpoints are overall survival (OS) rate of these patients, metastatic distribution of LNs in different histological subtypes of NSCLC, and consistency between frozen and paraffin pathology reports in determining the tumor invasiveness. Discussion: The results of this study will validate the necessity of LND in the lower mediastinum in the patients with early-stage NSCLC located in the apical segment with CTR >0.5 at CT scan. Trial Registration: ClinicalTrials.gov Identifier NCT06031246.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.